MAGIC TRIAL in gastric cancer
Reading File
search_medical_text
MAGIC trial perioperative chemotherapy gastric cancer ECF
search_medical_text
gastric cancer perioperative chemotherapy survival outcomes resection
GradeResponse
GradeResponse
MAGIC Trial — Perioperative Chemotherapy in Gastric Cancer
Background
The MAGIC trial (Medical Research Council Adjuvant Gastric Infusional Chemotherapy) was a landmark randomized controlled trial published by Cunningham et al. in the NEJM (2006) that established perioperative chemotherapy as a standard of care for resectable gastric cancer in the West.
Study Design
| Feature | Detail |
|---|---|
| Trial type | Phase III RCT |
| Population | Resectable gastric or lower esophageal adenocarcinoma (stage II–III) |
| Arms | Perioperative ECF chemotherapy + surgery vs. surgery alone |
| n | 503 patients |
| Setting | UK multicenter |
Chemotherapy Regimen — ECF
3 cycles pre-op + 3 cycles post-op:
- Epipodophyllotoxin → Epicirubicin 50 mg/m² IV day 1
- Cisplatin 60 mg/m² IV day 1
- Fluorouracil (5-FU) 200 mg/m²/day continuous IV infusion, days 1–21
Each cycle = 21 days; 3 pre-operative cycles, then surgery, then 3 post-operative cycles (if tolerated).
Key Results
| Endpoint | Surgery Alone | Perioperative ECF + Surgery | Significance |
|---|---|---|---|
| 5-year overall survival | 23% | 36% | HR 0.75, p = 0.009 |
| Progression-free survival | Shorter | Significantly longer | HR 0.66 |
| Curative resection rate (R0) | 69% | 79% | Favored chemo arm |
| Tumor downstaging | — | Significant (smaller, less nodal involvement) | — |
The survival benefit translated to a 13% absolute improvement in 5-year OS and a 25% relative reduction in the risk of death.
Pathologic Findings
Perioperative chemotherapy led to significant tumor downstaging:
- Smaller tumor size
- Fewer positive lymph nodes
- Higher proportion of T1/T2 tumors in the chemotherapy arm vs. T3/T4 in the surgery-alone arm
Tolerability & Completion
- Only about ~42% of patients who started pre-operative chemotherapy actually completed all 3 post-operative cycles, highlighting a significant challenge in the perioperative approach
- The most common toxicities were nausea, neutropenia, and fatigue
Significance & Impact
- Established perioperative chemotherapy as a standard of care for medically fit patients with cTNM stage II–III resectable gastric cancers (Harrison's, p. 2455)
- Demonstrated that neoadjuvant chemotherapy can downstage tumors, increasing R0 resection rates
- Prompted subsequent trials (FLOT4, FNCLCC/FFCD) that further refined the perioperative approach
- The FLOT4 trial later superseded ECF with FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), showing superior OS (50% vs. 45% 3-year OS), making FLOT the current preferred regimen in Western practice
Current Practice (Post-MAGIC)
| Approach | Regimen | Evidence |
|---|---|---|
| Preferred perioperative | FLOT × 4 pre-op + 4 post-op | FLOT4 trial (Al-Batran, NEJM 2019) |
| Alternative | ECF/EOF/ECX/EOX | MAGIC trial |
| Adjuvant chemoradiation | 5-FU + RT (MacDonald) | INT-0116 (US, post-op) |
| Adjuvant chemo (Asia) | S-1 or capecitabine + oxaliplatin | ACTS-GC, CLASSIC trials |
Bottom line: The MAGIC trial was the first major RCT to demonstrate that wrapping surgery with systemic chemotherapy (ECF) significantly improves survival in resectable gastric cancer, shifting the paradigm from surgery-first to a multimodality approach. It remains a foundational reference even though FLOT has now become the preferred regimen.
This is a shared conversation. Sign in to Orris to start your own chat.